Leonard S. Schleifer

2021

In 2021, Leonard S. Schleifer earned a total compensation of $6.5M as President and Chief Executive Officer at Regeneron Pharmaceuticals, a 95% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$4,030,584
Salary$1,767,800
Other$672,130
Total$6,470,514

Schleifer received $4M in non-equity incentive plan, accounting for 62% of the total pay in 2021.

Schleifer also received $1.8M in salary and $672.1K in other compensation.

Rankings

In 2021, Leonard S. Schleifer's compensation ranked 1,950th out of 12,397 executives tracked by ExecPay. In other words, Schleifer earned more than 84.3% of executives.

ClassificationRankingPercentile
All
1,950
out of 12,397
84th
Division
Manufacturing
738
out of 5,492
87th
Major group
Chemicals And Allied Products
284
out of 2,367
88th
Industry group
Drugs
243
out of 2,090
88th
Industry
Pharmaceutical Preparations
159
out of 1,537
90th
Source: SEC filing on April 21, 2022.

Schleifer's colleagues

We found five more compensation records of executives who worked with Leonard S. Schleifer at Regeneron Pharmaceuticals in 2021.

2021

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

2021

Robert Landry

Regeneron Pharmaceuticals

Chief Financial Officer

2021

Andrew Murphy

Regeneron Pharmaceuticals

Executive Vice President, Research

2021

Joseph LaRosa

Regeneron Pharmaceuticals

General Counsel

2021

George Yancopoulos

Regeneron Pharmaceuticals

Chief Scientific Officer

News

You may also like